ABSTRACT
INTRODUCTION AND OBJECTIVES
Alzheimer's disease (AD) is a progressive and fatal neurodegenerative disease, leading to cognitive and memory deterioration, progressive impairment of daily living activities and a variety of neuropsychiatric symptoms and behavioral changes. It is also the leading cause of dementia, accounting for 50-70% of all dementias worldwide according to World Health Organization (WHO) with associated costs around US$ 604 billions in 2010 (1) . In Brazil, the prevalence of dementia among the elderly is estimated to be 7,1% (approximately 1.1 million people), being AD responsible for 55% of all cases (2) .
Although the cause of AD is not yet fully understood, it is known that t h e d i s e a s e i s r e l a t e d t o a n o n g o i n g s y n a p t i c l o s s a n d neurodegeneration, leading to classical clinical features of AD (amnesic memory impairment, deterioration of language and visuospatial effects). On the other hand, it is known that there is a link between the intake of certain nutrients, cognitive function and the risk of AD, where nutrition is believed to play a role in the early process leading to the development of AD (3) . Epidemiological data on diet and cognitive decline in humans suggests that certain macro and micronutrients may have a preventive effect whereas deficiencies of important nutrients are identified as risk factors for cognitive impairment (4, 5) . Therefore, increasing the intake of these nutrients can improve cognitive function and reduce the risk of AD.
Souvenaid® is a medical food -an enriched nutritional formula -that contains theses specific nutrients that are reported to be deficient in patients with AD and have been shown to be beneficial for people with the disease. Clinical studies demonstrate that the dietary management with Souvenaid® for 12 to 24 weeks results in a significant improvement in memory in patients with early AD, being the nutrition formula an option to treat patients with AD in Brazil. In view of that, this study aims to estimate the budget impact of introducing Souvenaid® for the dietary management of mild AD at the Brazilian public healthcare system.
METHODS
An age related incidence of AD approach was used (Figure 1 ). Population size, according to different age categories, was derived from Brazilian statistics (IBGE) and combined with age related incidence of AD in Brazil (6) to estimate the number of patients per age stratum (Table 1) . Mean cost of AD was derived from a 7-state Markov model developed to estimate the effect of Souvenaid® for mild AD versus no dietary management (NDM) of mild AD and combined with demographic data in each age stratum. Only direct costs, obtained from a public hospital in Brazil, were considered and an estimated growth of 2,4% per year was applied for population above 65 years (Tables 2 and 3 ). The difference between Souvenaid® group and NDM was reflected on the 5-year budget impact estimated for SUS. The cost per unit of Souvenaid considered in the model was Brz 11.25. 
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RESULTS
Considering a market penetration of 10%, 13%, 15%, 17% and 20% each year, the estimated number of patients under Souvenaid® treatment is 11,002, 15,733, 19,969, 24,894 and 32,216, respectively, for years 1-5. Compared to NDM, the inclusion of Souvenaid® in the protocol of mild AD shows a potential budget impact of approximately Brz 3.9 million (US$ 1.8 million) for 5 consecutive years (Table 4 ). 
CONCLUSIONS
The use of Souvenaid®, a new approach in the management of mild AD, can benefit approximately 100,000 patients with AD in 5 years and it is estimated to have a relatively small budget impact to SUS, since the projections of cost of disease for the same period are Brz 154 million and potential budget impact of approximately Brz 3.9 million.
